Amplia Therapeutics Ltd. (ATX)
ASX ASX Primary Summary
Amplia Therapeutics Ltd. Dividends
Amplia Therapeutics Ltd. Earnings
| 30 May 2025 Date | | - Cons. EPS | - EPS |
| 28 May 2025 Date | | - Cons. EPS | - EPS |
| 18 Nov 2024 Date | | - Cons. EPS | - EPS |
| 23 Aug 2024 Date | | - Cons. EPS | - EPS |
| 30 May 2024 Date | | - Cons. EPS | - EPS |
| 30 May 2025 Date | | - Cons. EPS | - EPS |
| 28 May 2025 Date | | - Cons. EPS | - EPS |
| 18 Nov 2024 Date | | - Cons. EPS | - EPS |
| 23 Aug 2024 Date | | - Cons. EPS | - EPS |
| 30 May 2024 Date | | - Cons. EPS | - EPS |
Amplia Therapeutics Ltd. (ATX) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Amplia Therapeutics Ltd. ever had a stock split?
Amplia Therapeutics Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. CEO | ASX Exchange | AU0000023822 ISIN |
| Australia Country | - Employees | - Last Dividend | 30 Apr 2018 Last Split | - IPO Date |
Overview
Amplia Therapeutics Limited is an Australian pharmaceutical company dedicated to the development of novel treatments targeting cancer and fibrotic diseases. The company's primary focus is on the development of focal adhesion kinase (FAK) inhibitors, a promising area of research with potential applications in a range of serious conditions. Originally established in 2000 as Innate Immunotherapeutics Limited, the company underwent a rebranding to Amplia Therapeutics Limited in September 2018. Headquartered in Melbourne, Australia, Amplia Therapeutics is spearheading its research and development efforts to bring new therapeutic options to patients globally. Their collaborative efforts with the Garvan Institute of Media Research in Sydney further highlight their commitment to advancing medical research and improving patient outcomes.
Products and Services
AMP945
AMP945 is a leading product in Amplia Therapeutics' portfolio, developed as an inhibitor of FAK. It is aimed at treating pancreatic cancer and idiopathic pulmonary fibrosis, along with other solid tumor and fibrotic disease indications. AMP945 has successfully completed Phase I clinical trials, showcasing its potential as a viable treatment option and paving the way for further development. The therapeutic focus of AMP945 on pancreatic cancer and idiopathic pulmonary fibrosis underscores Amplia's commitment to addressing these challenging and underserved medical conditions.
AMP886
Another significant product within Amplia Therapeutics' pipeline is AMP886. This compound is designed for the treatment of acute myeloid leukemia (AML) and certain solid tumors. By targeting specific pathways involved in cancer progression, AMP886 represents a strategic expansion of Amplia's research endeavors into both hematological malignancies and solid cancers. As part of Amplia's broader strategy, AMP886 exemplifies the company's ongoing efforts to develop targeted therapies that can provide new hope for patients facing challenging diagnoses.
Contact Information
